Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Other Gross PP&E Adjustments (2016 - 2025)

Sangamo Therapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $45.9 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 24.5% year-over-year to $45.9 million; the TTM value through Dec 2025 reached $45.9 million, up 24.5%, while the annual FY2025 figure was $45.9 million, 24.5% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $45.9 million at Sangamo Therapeutics, up from -$14.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $45.9 million in Q4 2023 and troughed at -$70.9 million in Q1 2022.
  • A 5-year average of -$24.0 million and a median of -$19.8 million in 2024 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 1013.48% in 2022 and later fell 19.82% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at -$3.3 million in 2021, then skyrocketed by 1013.48% to $30.4 million in 2022, then soared by 51.32% to $45.9 million in 2023, then fell by 19.82% to $36.8 million in 2024, then increased by 24.5% to $45.9 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for SGMO at $45.9 million in Q4 2025, -$14.4 million in Q3 2025, and -$15.1 million in Q2 2025.